Dapagliflozin in patients with COVID-19: truth or dare

In 2019, the DAPA-HF trial showed a substantial clinical benefit of dapagliflozin among patients with heart failure and reduced ejection fraction, regardless of the presence or absence of diabetes.1 For many people, this trial was a breaking point after years of speculation:2 SGLT2 inhibitors became not only a good medication for diabetes but also an excellent drug for cardiovascular disease….

Read the full article here

Related Articles